If you have ever sat across a regulatory team trying to prepare simultaneous dossiers for the US FDA, EMA, and CDSCO, you already know the feeling. It is not just about assembling data. It is about deciding which version of the truth each agency will accept, in which format, backed by which studies, and in what sequence. And in 2026, that task has become simultaneously more complex and, in some areas, meaningfully easier.
India is home to the world’s largest number of FDA-approved manufacturing facilities outside the United States. Indian generic and innovative pharma companies collectively export to over 200 countries. Yet, for many of these companies, global regulatory submissions remain a source of significant rework, delays, and unexpected costs. The root cause, more often than not, is the gap between ICH guidelines and local regulatory requirements.
What makes 2026 particularly significant is that this gap is actively narrowing in some dimensions and widening in others. Several foundational ICH guidelines have been finalized or adopted in 2025, India has introduced its most meaningful regulatory reform in years through the NDCT Amendment Rules 2026, and new EU pharmaceutical legislation is reshaping the market access landscape in Europe. This blog is a practical guide for Indian pharma regulatory teams trying to build submission strategies that are current, efficient, and built to last.
Understanding ICH Guidelines: The Global Baseline in 2026
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, or ICH, exists to reduce the duplication of technical work across regulatory submissions globally. The concept is that if a drug is developed and tested to an internationally agreed standard, it should not need to repeat the same exercise for every market. ICH does not approve drugs individual agencies do. But it defines the scientific and procedural floor that major markets build on.
The ICH framework spans four domains. Quality guidelines the Q series address pharmaceutical development, risk management, manufacturing, and lifecycle management. Safety guidelines the S series govern non-clinical testing. Efficacy guidelines the E series cover clinical trial design, GCP, and statistical methodology. Multidisciplinary guidelines the M series define how all of this is packaged and submitted, most notably through the Common Technical Document or CTD format under ICH M4.
What is important to understand in 2026 is that the ICH framework itself has just gone through one of its most active update cycles in recent memory. Several guidelines that were in draft or consultation for years have now been formally adopted, and new areas are being brought into the harmonization fold for the first time.
Key ICH updates that are now in force or under active implementation:
- ICH E6(R3) – Good Clinical Practice (GCP), finalized January 2025: This is one of the most consequential GCP updates in nearly three decades. After years in consultation, the ICH E6(R3) guideline was formally adopted in January 2025. The FDA adopted it on September 9, 2025, and the EMA made it effective from July 23, 2025 for all EU clinical trials. E6(R3) restructures the original framework significantly: it introduces a separate overarching Principles document, Annex 1 covering interventional clinical trials, and a forthcoming Annex 2 addressing decentralized clinical trials, pragmatic trials, and the use of real-world data within trial designs. For Indian pharma companies running global trials, this means rethinking monitoring plans, data governance frameworks, and sponsor oversight processes to meet the new risk-based, quality-by-design model.
- ICH M11 CeSHarP, adopted November 2025: The ICH M11 guideline on Clinical Electronic Structured Harmonised Protocol was adopted at the November 2025 ICH Assembly in Singapore and is now in its implementation phase. It introduces a standardized format and data structure for clinical trial protocols, including a protocol template and technical specification that enable electronic exchange of protocol information across agencies. For Indian sponsors managing multi-regional trials, this changes how clinical protocols will need to be authored and submitted going forward.
- ICH M14, adopted September 2025: ICH M14 sets a global standard for pharmacoepidemiological studies that use real-world data for safety assessment. It introduces harmonized expectations around evidence quality, protocol pre-specification, and statistical rigor for RWD-based safety submissions. This is directly relevant for Indian companies managing post-market pharmacovigilance obligations across multiple markets.
- ICH E22 and E23 – New guidelines under development: ICH E22 on Patient Preference Studies has been released for public consultation, with comments open in Europe until April 2026. ICH E23 on Real-World Evidence for Effectiveness Decisions has been approved as a concept paper by the ICH Assembly. These are early-stage but signal the direction the framework is heading: toward patient-centered evidence and RWE as a primary evidentiary tool, not just a supplement.
The practical implication for Indian regulatory teams is that ICH compliance in 2026 is not the same as ICH compliance in 2023. If your SOPs, dossier templates, and clinical trial frameworks were last reviewed before mid-2025, they need to be updated.
Comparing India, US, EU, and APAC: Where the Real Differences Lie in 2026
Understanding where each major market deviates from the ICH baseline is the most important analytical step before planning any global submission. In 2026, some of these deviations have shifted significantly, particularly in India and the EU.
India (CDSCO) – Significantly Updated in 2026
India has introduced its most substantive regulatory reforms in years through the New Drugs and Clinical Trials (Amendment) Rules, 2026, notified on January 20, 2026 and effective from March 7, 2026. These changes are directly relevant to how Indian pharma companies plan development timelines and submission strategies.
The NDCT Amendment Rules 2026 introduce three key changes:
- Prior intimation replacing prior approval for low-risk BA/BE studies: Companies can now initiate single-dose, two-period, two-sequence, two-treatment bioavailability and bioequivalence studies in healthy adult volunteers by filing an online intimation via Form CT-05 on the SUGAM portal, without waiting for prior CDSCO approval. CDSCO processes approximately 4,500 BA/BE applications annually; this change is expected to substantially reduce startup delays across this high-volume pipeline. Importantly, high-risk drug categories including sex hormones, cytotoxic drugs, beta-lactam antibiotics, biologics containing live microorganisms, and narcotic and psychotropic substances continue to require prior approval.
- Prior intimation for non-commercial manufacture of lower-risk drugs: Manufacturing new drugs or investigational new drugs for analytical or non-clinical testing can now proceed on prior intimation via Form CT-10, replacing the requirement for a formal test license from the Central Licensing Authority for specified categories.
- Approval timelines cut from 90 to 45 working days: For drug categories that continue to require formal CDSCO approval rather than prior intimation, the statutory processing timeline has been halved from 90 working days to 45 working days.
Two additional CDSCO updates are material for 2026. First, offline submissions for Cell and Gene Therapeutics Products clinical trial applications are no longer accepted as of October 24, 2025; all CGTP applications must go through the SUGAM portal. Second, CDSCO is developing a Digital Drugs Regulatory System (DDRS) to modernize its submission and review infrastructure, with a vendor selection process underway through mid-2026.
On the data governance side, India’s Digital Personal Data Protection Rules 2025, notified in November 2025 under the DPDP Act 2023, introduce an 18-month phased compliance timeline. For pharma companies collecting real-world data from Indian patients for regulatory submissions whether for pharmacovigilance, observational studies, or registry-based research this framework adds a new compliance layer that must be factored into data collection protocols and Data Processing Agreements with CROs and technology vendors.
United States (FDA)
The FDA remains the most demanding adopter of ICH guidelines and in many areas exceeds them. Two significant 2025 developments shape the FDA landscape for Indian companies in 2026. First, the FDA adopted ICH E6(R3) on September 9, 2025, meaning all clinical trials conducted under IND must now align with the revised GCP framework, including updated requirements for risk-based monitoring, data governance, and decentralized trial oversight.
Second, in January 2025, the FDA released draft guidance proposing a risk-based credibility framework for AI models used in regulatory decision-making. This has practical implications for Indian companies using AI-assisted tools in dossier preparation, signal detection, or bioequivalence modeling. Validation requirements for AI-generated data are being tightened, and companies that use such tools without proper documentation risk receiving Complete Response Letters citing insufficient justification for AI-generated inputs.
One operational note worth flagging: the US federal government shutdown that ran through October and the first half of November 2025 resulted in the FDA being unable to accept new drug submissions for that period. While this was a temporary disruption, it caused ripple effects on submission timing and review milestones for companies with applications in that window. This is a useful reminder that submission timelines should always include buffer for regulatory operational disruptions, not just scientific review cycles.
Europe (EMA and New EU Pharmaceutical Legislation)
Europe is in the middle of a major legislative transition. The European Council adopted a consensus position on new EU pharmaceutical regulation and directive in June 2025. This package will replace the existing Regulation 726/2004 and Directive 2001/83/EC and will introduce modulated data exclusivity periods ranging from 8 to 12 years (depending on factors like unmet medical need and paediatric development), supply resilience obligations, and regulatory sandboxes for novel therapies. Final adoption is expected between late 2026 and early 2028, with full implementation following an 18-month transition period. Indian companies planning EU submissions or lifecycle strategies beyond 2027 should factor this transition into their regulatory roadmaps now.
The EMA also made ICH E6(R3) effective from July 23, 2025, for all clinical trials conducted in the EU. This means Indian sponsors running EU clinical sites must align their monitoring plans, data management systems, and quality management approaches with the new GCP framework. The EMA has also published updated Good Manufacturing Practice regulations for active substances under Commission Implementing Regulation (EU) 2025/2154, applicable from July 16, 2026, which affects Indian API manufacturers supplying to EU markets.
On AI, the EMA and FDA have jointly developed common principles for the use of AI in medicine development, published in 2025. The EU AI Act is also now fully applicable by August 2027 and classifies healthcare-related AI systems as high-risk, imposing stringent validation, traceability, and human oversight requirements. Indian companies building AI-assisted regulatory workflows should begin designing to these standards now.
APAC Markets (Japan, South Korea, ASEAN)
Japan’s PMDA continues to adopt ICH guidelines but maintains Japan-specific requirements for local language package inserts and domestic bridging studies under ICH E5 for products where ethnicity-related pharmacokinetic differences may be relevant. Japan is actively implementing ICH E6(R3) and ICH M11 CeSHarP, and Indian companies running Japanese clinical sites or filing PMDA applications should expect these standards to be applied in review. South Korea’s MFDS continues its alignment with ICH, with Korean-language submissions required for certain product categories.
ASEAN markets continue to use the ASEAN Common Technical Dossier format, which closely follows ICH CTD structure but with variations in local labelling requirements, stability conditions, and post-market surveillance obligations. Mutual recognition of GMP inspections among ASEAN members is advancing but remains incomplete, meaning Indian manufacturers still need to manage country-specific GMP certification processes for several ASEAN markets.
Local Adaptation Without Rework: Building a Smarter Dossier Architecture for 2026
This is where most Indian regulatory teams can unlock significant efficiency. The typical approach is to prepare a primary dossier for one market often the FDA or EMA and then adapt it for others. The problem is that adaptation often becomes a full rebuild because the original dossier was not structured with modularity in mind.
The smarter approach is to design the core dossier around the ICH CTD format from the start, treating the global core as a clean, market-agnostic foundation and layering country-specific requirements as modular add-ons. In 2026, this architecture needs to account for two new structural dimensions.
The first is ICH M11 CeSHarP. Now formally adopted, ICH M11 standardizes the format and data content of clinical trial protocols in a machine-readable, electronically exchangeable structure. Indian companies planning global trials in 2026 and beyond should begin authoring protocols using the CeSHarP template and technical specification. This will not only align with agency expectations in ICH member regions but will significantly reduce the effort of adapting protocols for each national competent authority, since the structured format facilitates electronic extraction and review rather than manual assessment.
The second is the NDCT 2026 prior intimation framework. For Indian regulatory teams managing domestic and global BA/BE programmes simultaneously, the new prior intimation route changes timeline planning materially. Bioequivalence studies that previously required waiting 90 working days for CDSCO approval can now be initiated after filing intimation and receiving acknowledgment. This compresses the domestic development cycle significantly and, in many cases, removes India from the critical path in global development plans.
The broader dossier architecture principle remains the same: keep Modules 2 through 5 as ICH-compliant global core documents, and build country-specific Module 1 packages for each agency along with market-specific annexes for areas of local divergence. The 2026 updates make this architecture even more valuable because the ICH baseline itself is now more robust and more widely adopted than it was even two years ago.
Practical Tips for Indian Pharma Global Submissions in 2026
Here is what actually works in practice, updated for the regulatory environment as it stands in 2026.
Update your GCP framework to ICH E6(R3) now, not when your next trial starts.
ICH E6(R3) is now in force for EMA (from July 2025) and FDA (from September 2025). If your clinical trial master file templates, monitoring plans, quality management systems, and investigator site agreements still reference E6(R2), they are out of date. The new framework requires a documented quality management system for clinical operations, a risk-based approach to oversight that goes beyond traditional Source Data Verification, and updated data governance provisions. This is not a light refresh it is a substantive restructuring of how clinical oversight is documented and implemented.
Leverage the NDCT 2026 prior intimation route strategically.
For Indian companies running BA/BE studies, the new prior intimation mechanism under amended Rule 52 is a genuine timeline accelerator. However, it requires that you have your study protocols, site qualifications, ethics committee approvals, and analytical method validations ready to proceed immediately upon acknowledgment, since you will not have the prior approval period to complete these preparations. Companies that treat the prior intimation as permission to start from scratch will not see the timeline benefit. Those who treat it as a green light to execute a pre-prepared study plan will. Build your BA/BE site readiness and protocol finalization to precede the intimation filing, not follow it.
Adopt ICH M11 CeSHarP protocol structure for all new global trials.
ICH M11 is in its implementation phase. While agencies may not yet mandate it in all markets, using the CeSHarP structured protocol template for new global trials is a forward-looking investment. It reduces protocol variability across sites and regions, makes electronic exchange with agencies more efficient, and aligns your trial documentation with where the global standard is heading. For Indian sponsors managing large multi-centre international studies, this translates into meaningful operational savings.
Review your RWD data collection arrangements against India’s DPDP Rules 2025.
India’s Digital Personal Data Protection Rules 2025 impose a structured compliance framework on how personal data, including health and patient data, is collected, processed, and transferred. Pharma companies collecting real-world data from Indian patients for pharmacovigilance reporting, registry studies, or effectiveness research must ensure their data processing agreements, consent frameworks, and data transfer mechanisms comply with the DPDP framework within the 18-month phased timeline. This is not optional, and the rules have implications for how Indian RWD can be incorporated into global regulatory submissions.
Start regulatory intelligence tracking for the new EU pharmaceutical legislation.
The new EU pharmaceutical regulation is not in force yet, but final adoption is expected between late 2026 and early 2028. The introduction of modulated exclusivity periods, supply resilience obligations, and regulatory sandboxes for novel therapies will change how Indian companies structure their EU market access strategies, particularly for generics and biosimilars. Regulatory affairs teams should begin monitoring the legislative negotiation progress now and run scenario planning for how different exclusivity models would affect their EU pipeline timelines.
Engage with agencies earlier than you think you need to.
FDA Pre-IND meetings, EMA Scientific Advice procedures, and CDSCO Pre-submission meetings are available for a reason. Many Indian companies still skip them. The cumulative cost of even one major clinical study redone because of a misaligned development approach far exceeds the investment in early agency engagement. This is especially true in 2026, where multiple major guideline updates mean that what was acceptable two years ago may no longer be the agency’s expectation today.
Common Compliance Pitfalls Indian Pharma Companies Fall Into
These are the patterns that surface repeatedly in global submissions from Indian companies. In 2026, some of them have new dimensions worth naming.
- Treating ICH E6(R2) as still current. With E6(R3) now adopted by both the FDA and EMA, clinical trial documentation referencing the previous version will be flagged in regulatory submissions and inspections. Updating GCP framework documentation is not a back-office exercise it affects inspection readiness, CRO oversight agreements, and data governance at a fundamental level.
- Underestimating CDSCO’s continued local data requirements despite reforms. The NDCT 2026 amendments have eased specific procedural hurdles, particularly around BA/BE approval timelines. They have not changed the underlying requirement for Indian bridging data or local clinical evidence for new drugs seeking marketing authorization in India. The prior intimation route accelerates study startup it does not remove the need for India-specific data in the NDA dossier.
- Using AI tools in submission preparation without validation documentation. With both the FDA and EMA now actively developing AI governance frameworks for regulatory submissions, the use of unvalidated AI tools in dossier preparation, signal detection, or bioequivalence modeling is a growing inspection risk. If your regulatory team is using AI-assisted tools, you need audit trails, validation documentation, and a clear rationale for how AI outputs were reviewed and verified before being incorporated into submissions.
- Poor document version control across simultaneous submissions. When managing multiple submissions in parallel, different document versions can end up in different dossiers. This creates inconsistencies that agencies flag during review and that become serious problems during inspections. A controlled document management system with clear version histories is essential, not optional.
- Inadequate vendor oversight for outsourced activities. Regulatory accountability for outsourced BA/BE studies, stability testing, and analytical method validation rests with the MAH, not the CRO or CMO. Data integrity findings from outsourced activities count against the MAH in inspections. Audit your vendors as rigorously as you audit your own operations.
- Failing to account for the EU legislative transition in pipeline planning. Companies with EU generic or biosimilar applications that straddle the transition to the new pharmaceutical regulation need to understand how the modulated exclusivity periods in the new framework will affect their market entry timelines. Planning a product launch that assumes the current exclusivity model may produce materially incorrect commercial projections.
FAQ: ICH Submission Queries from Indian Pharma Teams
Q1. Does following ICH guidelines mean my dossier will be accepted in all markets?
No, but it is the strongest foundation you can build on. ICH compliance means your dossier meets the international technical baseline accepted by the FDA, EMA, PMDA, and other major markets. What it does not cover is the market-specific Module 1 content, local language requirements, bridging data expectations, and post-market obligations that each agency layers on top of the ICH core. In 2026, this is especially relevant because three major ICH guidelines E6(R3), M11, and M14 have all been recently updated or adopted, meaning your ‘ICH compliant’ baseline may be more outdated than you think if your templates have not been refreshed since mid-2025.
Q2. What does the NDCT Amendment Rules 2026 mean practically for Indian pharma companies?
It is one of the most meaningful procedural reforms CDSCO has introduced in years. For BA/BE studies, the change from prior approval to prior intimation for single-dose, two-period, crossover studies in healthy volunteers removes a regulatory bottleneck that added months to development timelines. For non-commercial manufacture of lower-risk drugs for analytical testing, the test license requirement has been replaced by a simpler intimation mechanism. And for activities that still require approval, the timeline has been halved from 90 to 45 working days. Practically, this means Indian companies can compress domestic development cycles significantly provided they have the operational readiness to execute immediately upon filing intimation rather than using the former approval wait time for preparation.
Q3. How does ICH E6(R3) change what Indian sponsors need to do for global clinical trials?
ICH E6(R3), finalized in January 2025 and now in force across the EU and US, requires sponsors to implement a formal Quality Management System for clinical operations, adopt a risk-based approach to monitoring that goes beyond traditional source data verification, and update data governance frameworks to align with the new structured requirements. For Indian sponsors managing international trials, this means updating clinical trial master file templates, monitoring plans, investigator site agreements, and CRO oversight frameworks. The guideline also introduces new provisions for decentralized clinical trial elements in its forthcoming Annex 2, which will be particularly relevant for Indian companies exploring remote and hybrid trial models.
Q4. How should an Indian company approach simultaneous submissions to the FDA, EMA, and CDSCO?
Build the global core dossier in ICH CTD format covering Modules 2 through 5 with ICH-compliant content, then create country-specific Module 1 packages and market-specific annexes. For clinical protocols, use the ICH M11 CeSHarP structured template from the start of your next global trial this reduces the effort of adapting protocols across agencies substantially. For BA/BE, design your protocol to meet the most demanding agency requirements first and ensure your CDSCO prior intimation filing is supported by a fully prepared study package ready for immediate execution. And engage agencies through scientific advice and pre-submission meetings before finalizing your development strategy, not after.
Q5. What is ICH M11 CeSHarP and does it affect Indian pharma companies now?
ICH M11 CeSHarP is the Clinical Electronic Structured Harmonised Protocol guideline, adopted at the ICH Assembly in November 2025. It introduces a standardized, machine-readable format for clinical trial protocols that enables electronic exchange across regulatory agencies globally. It is in its implementation phase, meaning agencies are not yet mandating it universally, but companies that adopt it for new global trials now will build a structural advantage: cleaner protocol documentation, reduced agency queries on protocol completeness, and better alignment with the direction that all ICH-member regulators are heading. For Indian sponsors running multi-regional trials, CeSHarP reduces protocol adaptation effort across FDA, EMA, PMDA, and other agencies significantly.
Q6. We are a mid-sized Indian generics company. Where do we start with 2026 regulatory alignment?
Start with three things. First, do a gap assessment of your GCP documentation against ICH E6(R3) this is non-negotiable for any company running or planning global clinical trials. Second, review your CDSCO BA/BE pipeline against the new prior intimation criteria under the NDCT 2026 amendments and restructure your study startup processes to capitalise on the reduced timelines. Third, audit your dossier templates for your two or three priority export markets and identify where the ICH core needs market-specific overlays based on 2025–2026 guidance updates. None of this requires large teams. It requires targeted regulatory intelligence and the willingness to treat compliance infrastructure as a strategic investment rather than an overhead cost.
Navigating the space between ICH guidelines and local pharma regulations has always required precision and current knowledge. In 2026, it also requires something else: the recognition that the ICH baseline itself has just shifted substantially. ICH E6(R3) is in force. ICH M11 is adopted. ICH M14 has raised the bar for RWE-based safety submissions. And in India, the NDCT 2026 amendments have opened faster pathways that reward operational readiness.
Indian pharma companies that refresh their regulatory frameworks to reflect these changes not just the local rules, but the updated ICH baseline will be better positioned for faster approvals, fewer agency queries, and cleaner inspection outcomes. Those that are still operating on 2022 or 2023 assumptions will increasingly find themselves in gap-closure mode rather than growth mode.
If you want to know exactly where your current submission strategy stands against the 2026 regulatory landscape across your priority markets, a structured regulatory gap assessment is the most efficient starting point. Speak with a regulatory expert who understands both the updated ICH framework and the specific market requirements of your target markets.